Who is sponsoring NCT04837924?

NCT04837924 is sponsored by General Hospital Sveti Duh.

What drugs are being tested in NCT04837924?

Interventions in NCT04837924: fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml), paracetamol 1 gram IV, Rescue analgesic tramadol 100 mg IV if needed, Sham injection.

What condition does NCT04837924 study?

NCT04837924 studies Hip Fractures.

Is NCT04837924 still recruiting?

NCT04837924 is currently completed. Last updated 3 August 2022.

Last reviewed 2022-08-03 · How we verify

NCT04837924: BLOCKPAIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fascia Iliaca Compartment Block for Pain Management in Hip Fracture Patients

Completed Phase 4 Last updated 3 August 2022

What this trial tests

Phase 4 trial testing fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml) in Hip Fractures in 80 participants. Completed in 27 May 2022.

Timeline

21 April 2021

Primary endpoint
26 May 2022

27 May 2022

Quick facts

Lead sponsor	General Hospital Sveti Duh
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	80
Start date	21 April 2021
Primary completion	26 May 2022
Estimated completion	27 May 2022
Sites	1 location across Croatia

Drugs / interventions tested

fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml)
paracetamol 1 gram IV — full drug profile →
Rescue analgesic tramadol 100 mg IV if needed — full drug profile →
Sham injection — full drug profile →

Conditions studied

Hip Fractures — all drugs for Hip Fractures →

Sponsor

General Hospital Sveti Duh

Who can join

65 and older, any sex, with Hip Fractures. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BLOCKPAIN is a randomized controlled study, 80 participants. The participants will be hip fracture patients in Emergency Medicine Department in Clinical Hospital "Sveti Duh", Zagreb, Croatia. Upon patient arrival inclusion and exclusion criteria will be established. After signing the informed consent form participant will be randomized in one of two study groups. One study group is fascia iliaca compartment block (FICB), the other is placebo. All participants will be given paracetamol 1 gram IV as standard care. If needed, rescue analgesic will be tramadol 100 mg in 100 ml saline IV. The time frame is 24 hours after the FICB or placebo procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hip Fractures

Currently open trials in the same condition.

NCT07239817 — PENG Block + LIA For Endoprosthesis Surgery With Anterior Approach · NA · recruiting
NCT07002723 — Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality · NA · recruiting
NCT06893406 — Cervical Myelopathy in Hip Fracture Patients · NA · recruiting
NCT06565910 — Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG) · Phase 4 · recruiting
NCT06455813 — What Laxative Should be Used After Hip Fracture Surgery? · Phase 4 · recruiting

Other General Hospital Sveti Duh trials

Trials by the same sponsor.

NCT07277556 — TURP Outcome Prediction Calculator Study · not yet recruiting
NCT07285408 — Sarcopenia and NMIBC Prognosis Study · not yet recruiting
NCT04607031 — Prognostic Accuracy of ST2 Dynamics in Ischemic Stroke Outcome · completed
NCT04276519 — Position-Induced Opening of the Intervertebral Foramen is Efficient to Treat an Acute Lumbosacral Radiculopathy Caused b · NA · completed
NCT03085862 — Lung Ultrasonography and Extravascular Lung Water · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04837924 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by General Hospital Sveti Duh
Last refreshed: 3 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04837924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing